NRx Pharmaceuticals

View the org chart displaying its 12 main executives

Most searched biographies at NRx Pharmaceuticals

• Steve Willard, Chief Executive Officer and Director
• Patrick Flynn, Director
• Chaim Hurvitz, Director

Popular executive movements at NRx Pharmaceuticals

• Janet Rehnquist has joined the company as Director  (posted on December 27 2023).

Create your alert
to follow the executive moves at NRx Pharmaceuticals.

NRx Pharmaceuticals has 1,860 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).

Popular M&A news in Pharmaceuticals

• MedMen has filed for bankruptcy protection  (posted on April 28 2024).
• AstraZeneca has announced the acquisition of Fusion Pharma  (posted on March 23 2024).
• AstraZeneca has announced the acquisition of Amolyt Pharma  (posted on March 19 2024).

Popular contacts in Pharmaceuticals

• Jean-Frédéric Paulsen - Executive Chairman of the Board at Ferring Pharmaceuticals
• Emma Walmsley - Chief Executive Officer and Director at GSK
• Danilo Cicmil - Supervisory Board Member at Galenika

Learn more about the Pharmaceuticals industry >

Press releases by NRx Pharmaceuticals

• NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
• NRx Pharmaceuticals Investors - Press Releases
• NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
• NRx Pharmaceuticals Investors - Press Releases
• NRx Pharmaceuticals Investors - Press Releases
• NRx Pharmaceuticals Investors - Press Releases
• NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
• NRx Pharmaceuticals Investors - Press Releases
• NRx Pharmaceuticals Investors - Press Releases
• NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
• View more press releases Close

Social media about NRx Pharmaceuticals

• NRx Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• NRx Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Patrick Flynn

Call NRx Pharmaceuticals at +1 484...

View the org chart

Register to receive your alert

Report an error